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 Current allergen immunotherapy approaches are limited by long treatment duration, cost 
and adverse reactions 
 Immune adjuvants may improve efficacy, durability and cost of allergen immunotherapy 
 Delta inulin (Advax™) is a well-tolerated and safe carbohydrate-based immune adjuvant 
 Jack Jumper ant venom immunotherapy is compatible with Advax adjuvant 




A major challenge in broader clinical application of Jack Jumper ant venom immunotherapy 
(JJA VIT) is the scarcity of ant venom which needs to be manually harvested from wild ants. 
Adjuvants are commonly used for antigen sparing in other vaccines, and thereby could 
potentially have major benefits to extend JJA supplies if they were to similarly enhance JJA 
VIT immunogenicity. The purpose of this study was to evaluate the physicochemical and 
microbiological stability and murine immunogenicity of low-dose JJA VIT formulated with a 
novel polysaccharide adjuvant referred to as delta inulin or Advax™. Jack Jumper ant venom 
(JJAV) protein stability was assessed by UPLC-UV, SDS-PAGE, SDS-PAGE immunoblot, 
and ELISA inhibition. Diffraction light scattering was used to assess particle size distribution 
of Advax; pH and benzyl alcohol quantification by UPLC-UV were used to assess the 
physicochemical stability of JJAV diluent, and endotoxin content and preservative efficacy 
test was used to investigate the microbiological properties of the adjuvanted VIT formulation. 
To assess the effect of adjuvant on JJA venom immunogenicity, mice were immunised four 
times with JJAV alone or formulated with Advax adjuvant. JJA VIT formulated with Advax 
was found to be physicochemically and microbiologically stable for at least 2 days when 
stored at 4 and 25°C with a trend for an increase in allergenic potency observed beyond 2 
days of storage. Low-dose JJAV formulated with Advax adjuvant induced significantly 
higher JJAV-specific IgG than a 5-fold higher dose of JJAV alone, consistent with a powerful 
allergen-sparing effect. The pharmaceutical data provides important guidance on the 
formulation, storage and use of JJA VIT formulated with Advax adjuvant, with the murine 
immunogenicity studies providing a strong rationale for a planned clinical trial to test the 






























Rapid onset, systemic allergic reactions to Jack Jumper ant (Myrmecia pilosula, JJA) sting 
represent a significant public health problem in the south-eastern and south-western part of 
Australia, affecting up to 3% of the population [1]. Immunotherapy for the prevention of 
stinging insect anaphylaxis involves the administration of increasing doses of purified insect 
venom to induce clinical tolerance, as reflected by a progressive reduction in venom-specific 
IgE and increase in IgG4 [2]. JJA venom immunotherapy (VIT) involving a large 
maintenance dose of 100 g of venom has been shown to be highly effective at preventing 
JJA sting anaphylaxis, reducing the risk of severe systemic sting reactions by 95% [3]. Real-
world experience shows efficacy comparable with yellow jacket and better than honeybee 
VIT [4]. The applicability of JJA VIT to the wider population, however, is limited by highly 
restricted JJA venom (JJAV) extract availability, production cost, and high incidence of 
adverse events [3-5]. 
An adjuvant that could facilitate a desirable immune response to JJAV and allow allergen 
dose reduction would have the potential to minimise adverse effects and reduce cost by 
reducing venom requirements [6]. A potential candidate adjuvant for VIT is the delta inulin-
based adjuvant, Advax™. Advax is based on the plant derived fructan inulin (β-D-[2→1] 
poly(fructo-furanosyl) α-D-glucose) [7]. Inulin has no immunological activity when in 
soluble form, but once formulated into delta inulin microparticles of 1-5 μm size, it has 
potent immune-adjuvant activity [8]. Advax has been shown in preclinical studies to enhance 
immunogenicity of a broad range of vaccines including influenza, hepatitis B virus (HBV), 
Japanese encephalitis, SARS coronavirus, HIV, listeria, RSV, and anthrax [9, 10]. The safety 
and efficacy of Advax have been shown in adult humans when formulated with HBV and 
influenza vaccines [9, 11, 12]. When combined with honeybee VIT and administered to 
individuals with honeybee-sting anaphylaxis, Advax was shown to be safe and well tolerated 
[13], and enhanced the immunogenicity of the honeybee venom with strongly enhanced 
venom-specific IgG4 responses [14], a potential marker of successful immunotherapy [15]. 
Understanding the stability of JJA VIT and its aggregation potential with Advax 
microparticles in a combined formulation is essential as aggregation or decomposition of 
allergen components in JJAV may affect their allergenic potency [16], which has been found 
to increase with storage in a previous study [17]. The objective of the current study was 
therefore to explore the stability and aggregation potential of JJA VIT and Advax in a 













Although there are currently no animal models of JJAV allergy, it was further necessary to 
demonstrate using a murine immunogenicity model that co-administration of JJA VIT with 
Advax was safe and well tolerated and that the inclusion of the Advax adjuvant was able to 














2. Materials and methods 
2.1. Materials 
Chemicals, reagents and consumables used in the experiments were as previously described 
[16]. Chemicals used in the formulation of JJA VIT products were of pharmacopoeial grade; 
sucrose and polysorbate 80 from Avantor (Centre Valley, PA, USA), benzyl alcohol from 
PCCA (Houston, TX, USA), sodium chloride 20% solution from AstraZeneca (North Ryde, 
NSW, Australia), sodium dihydrogen phosphate solution from Phebra (Lane Cove West, 
NSW, Australia), disodium hydrogen phosphate from SAFC (St. Louis, MO, USA), 0.9% 
sodium chloride from Pfizer (West Ryde, NSW, Australia), Water for Injection from Pfizer 
and Baxter (Old Toongabbie, NSW, Australia). Microbiological media and ATCC® strains 
microorganisms were from Oxoid (Basingstoke, Hampshire, UK). Pooled positive sera (PPS) 
with high JJAV-specific positive IgE levels was obtained from JJAV allergic individuals with 
clinically proven history of allergy, as previously described [16]. 
 
2.2. Jack Jumper Ant Venom Immunotherapy and Advax adjuvant 
JJAV Active Pharmaceutical Ingredient (API) was prepared as previously described [16] and 
formulated in 22% sucrose solution to produce clinical grade JJA VIT containing 1.1 mg/mL 
venom proteins. JJAV diluent solution containing 0.9% sodium chloride, phosphate buffer 
(pH 6.0; 10 mM), 0.05% polysorbate 80 and 0.9% benzyl alcohol was manufactured at the 
Pharmacy Department, Royal Hobart Hospital as previously described [17]. Advax adjuvant 
in buffered saline (pH 7.5-8.5) was supplied by Vaxine Pty Ltd (Bedford Park, Adelaide, 
Australia). The Advax adjuvant was prepared according to current Good Manufacturing 
Practice [8] and supplied as a sterile suspension containing 50 mg/mL delta inulin 
microparticles. 
 
2.3. Preparation of JJA VIT/Advax formulations and stability trial conditions 
For Advax-free samples, JJAV was diluted to 25 μg/mL using JJAV diluent. Where Advax 
was included in the formulation, JJA VIT and Advax were first diluted using JJAV diluent to 
50 μg/mL and 20 mg/mL, respectively. When the two diluted components were mixed in 
equal quantities this gave final concentrations of 25 μg/mL and 10 mg/mL, respectively, the 
planned doses to be used in the future human trial. For allergen potency studies, JJAV was 













μg/mL of venom and 5 mg/mL of Advax. Samples were prepared using aseptic techniques 
and packaged in U-100 insulin syringes (Terumo, Elkton, Maryland, USA), protected from 
light and stored at 4°C and 25°C for up to 28 days. 
 
2.4. Antigen extraction, efficiency of antigen extraction and control of samples pre-analysis 
Baseline samples were processed within 15 min post preparation. All stability samples were 
collected and processed after 2, 6, 24 and 48 hours, and the 25 μg/mL samples were also 
collected at 3, 7, 14, 21, and 28 days post storage. Except for the particle size analysis, where 
samples were analysed without antigen extraction, JJAV was extracted from the stability 
samples by centrifugation. Samples were transferred to Protein LoBind microtubes 
(Eppendorf AG, Hamburg, Germany) and centrifuged for 5 min at 5000 rpm (2348× g) and 
5°C (Eppendorf 5424R Microcentrifuge) to pellet the Advax particles. Supernatant was 
transferred to fresh microtubes and stored at ‒80°C until analysis. 
 
2.5. Analysis of JJAV allergen stability 
2.5.1. ELISA inhibition 
Allergenic potency in 25, 10, 1, and 0.1 μg/mL samples was analysed using JJAV IgE-
specific ELISA inhibition assay, as previously described [16]. Briefly, 96-well Amino 
Immobilizer plates (Nunc, Roskilde, Denmark) were coated overnight at 4°C with 100 μL of 
10 μg/mL JJAV in sodium carbonate (0.05 M, pH 9.6). Inhibition mixtures were prepared by 
adding between 0.15 and 4 ng of JJAV to 25 μL PPS and diluting to 100 μL with phosphate 
buffered saline (0.01 M, pH = 7.2) containing 0.05% polysorbate 20 (PBS-T) and 0.5% 
bovine serum albumin (BSA). JJAV in the inhibition mixtures was either baseline or stability 
samples as described in section 2.4. A positive control was prepared by diluting PPS 1:4 (v/v) 
in PBS-T with 0.5% BSA and negative control consisted of PBS-T with 0.5% BSA and 
incubated overnight at 4°C. Subsequently, venom coating solution was discarded and the 
plate was washed three times with PBS-T. The venom-coated plate was incubated with 100 
μL of inhibition mixtures, positive control and negative control for 60 min at room 
temperature (RT). The plate was washed three times with PBS-T, and 100 μL of biotinylated 
mouse monoclonal anti-human IgE antibody (1:2000 (v/v) dilution in PBS-T, clone HP6029, 
Life Technologies, Carlsbad, CA, USA) was added to each well and incubated in the dark for 
60 min at RT. The plate was washed three times with PBS-T, and then 100 μL of 













Diego, CA, USA) was added to each well and the plate was incubated in the dark for 20 min 
at RT. The plate was washed three times with PBS-T, and then 100 μL of 1-Step Ultra TMB-
ELISA (Thermo Fisher Scientific, Rockford, IL, USA) was added to each well and the plate 
was incubated in the dark for 30 min at RT. Colour development was stopped by adding 100 
μL of 2 M sulphuric acid and absorbance was read at 450 nm utilizing an ELISA plate reader 
(SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). Samples were run in triplicates, 
and the mean and standard deviation calculated. The percentage inhibition for each sample 
was calculated using the following equation: 
 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝐼𝑔𝐸 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (%) =  
𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛  𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛  𝑜𝑓 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛  𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
 
Allergenic potency of JJAV was measured as the amount of venom in solution that was 
required to inhibit 50% of IgE binding to the JJAV coated onto the plate. The stability of 
venom samples were calculated as a percentage relative to baseline samples. 
 
2.5.2. SDS-PAGE and SDS-PAGE resolved JJAV immunoblot 
The 25 μg/mL samples were concentrated to 0.5 mg/mL using a centrifugal filter device 
(Amicon Ultra-0.5 with 3 kDa nominal molecular weight limit, Merck Millipore, Darmstadt, 
Germany), after which they were mixed with SDS sample buffer and analysed by SDS-PAGE 
or SDS-PAGE immunoblot assay as previously described [16]. PPS was used in the SDS-
PAGE immunoblot assay. 
 
2.5.3. Ultra Performance Liquid Chromatography 
To assess Myr p allergen peptide changes, the 25 μg/mL venom samples were analysed by 
UPLC-UV using an Acquity H-series UPLC (Waters Corporation, Milford, Massachusetts, 
USA) coupled to an Acquity Photo Diode Array (PDA) detector. An Acquity UPLC BEH 
C18 column (2.1 x 100 mm x 1.7 micron particles) held at 40°C was used. The mobile phase 
flow rate was 0.35 mL/min and the solvent system was water:acetonitrile:1% trifluoroacetic 
acid in water (80:12:8, v/v/v) to (24:68:8, v/v/v) in a linear gradient over 12 min before re-
equilibration for 3 min to initial conditions. Triplicate injections of 40 μL were made and data 
for quantitative measurements of peak areas corresponding to the Myr p 1‒3 allergen 













3 at 7.52 min, and Myr p 1 at 8.39 min (Fig S1). Data were analysed using Waters MassLynx 
and TargetLynx software. The mean peak area for each allergen peptide was calculated and 
the analysis of remaining concentration of the allergen peptides was calculated as a 
percentage relative to baseline samples. 
 
2.6. Analysis of JJAV diluent stability 
2.6.1. Measurement of pH 
Sample(s) pH was measured using a calibrated pH meter (Hanna Instrument, Woonsocket, 
RI, USA). 
 
2.6.2. Benzyl alcohol determination 
Benzyl alcohol concentration was determined by UPLC-UV using the instrument and column 
described above. The mobile phase flow rate was 0.35 mL/min and the solvent system was an 
isocratic mixture of 1% acetic acid in water:acetonitrile (70:30, v/v). Quadruple injections of 
20 μL were made and data for quantitative measurements were extracted at 270 nm to 
maintain on scale signals. Benzyl alcohol eluted at 1.3 min and the peak area was determined 
using Waters TargetLynx software. Where benzyl alcohol-free Advax was added, the 
concentration of benzyl alcohol in the JJAV diluent was reduced by 19%, consistent with 
dilutional effect. 
 
2.7. Analysis of Advax stability 
Particle size of Advax (10 mg/mL) in the presence of JJAV (25 μg/mL) in diluent solution 
was determined by dynamic light scattering (DLS) using a Zetasizer Nano S (Malvern 
Instruments Ltd., Worcestershire, UK). Samples were mixed by vortexing to form a uniform 
suspension and transferred to UVette plastic cuvettes (Eppendorf AG). Sample compartment 
temperature was adjusted to 25°C before measurements were taken. Measurements were 
performed in triplicate and the average particle size (Z-Average size) and particle size 
distribution (via Polydispersity Index; PdI) were obtained [18]. 
 
2.8. Microbiological analysis 
2.8.1. Endotoxin content 
Samples were analysed for endotoxin contents using Limulus Amebocyte Lysate QCL-1000 














2.8.2. Antimicrobial Efficacy Test 
The antimicrobial efficacy of benzyl alcohol in JJAV diluent was evaluated using the United 
States Pharmacopoeia Antimicrobial Effectiveness Test (AET) [19]. The following challenge 
organisms were used: Candida albicans (ATCC 10231), Escherichia coli (ATCC 25922), 
and Staphylococcus aureus (ATCC 25923). Bacterial stock cultures were grown for 20-24 
hours in Tryptone Soya Broth and yeast stock culture was grown for 44-48 hours in Sabaroud 
Dextrose Broth. Microorganisms were harvested by centrifugation, washed, resuspended, and 
diluted in 0.9% normal saline to obtain a microbial count of approximately 1 x 108 colony 
forming units per mL (CFU/mL). Microbial suspensions were used within 30 min of harvest. 
For each challenge organism, AET was conducted in five replicates. Test samples consisting 
of 400 μL of JJAV diluent containing either JJAV (25 μg/mL) alone or with Advax (10 
mg/mL), were inoculated with the microbial suspension at 1.0% (v/v) to yield a final 
concentration between 1 x 105 and 1 x 106 CFU/mL and incubated at 23°C for up to 28 days. 
Aliquots (100 μL) were taken from each sample at days 7, 14 and 28, and the number of 
CFUs in each sample was determined using plate-count method. Positive control samples 
(400 μL of 0.9% normal saline) were inoculated with the microbial suspension at 1.0% (v/v) 
to yield a final concentration between 1 x 105 and 1 x 106 CFU/mL. A 100 μL aliquot was 
taken from each control sample at baseline and the number of CFUs was determined using 
plate-count method. Negative control samples were growth media (from the same batches) 
devoid of any manipulation. 
 
2.9. Murine immunogenicity studies 
To assess the potential of Advax to provide JJAV antigen-sparing, female BALB/c mice, 6 to 
8 week old were immunized 4 times intramuscularly at 2-week intervals with JJAV 2 μg 
(Royal Hobart Hospital, Tasmania, Australia) alone or formulated with Advax 1 mg (Vaxine 
Pty Ltd, Adelaide, Australia) versus JJAV 10 μg alone in 50 μL total injection volume. Blood 
samples were collected 2 weeks after the last immunization for measurement of JJAV-
specific IgG responses by ELISA. 
 
2.9.1. JJAV-specific antibody ELISA 
Mouse JJAV-specific IgG, IgG1 and IgG2a antibodies were determined by ELISA, as 













buffer (pH 5.0; 50 mM MES + 25 mM HEPES in PBS) was absorbed to 96 well plates, 
blocked with 0.2% Casein, then 100 µL of 1:200 dilution of sera was incubated for 2 hours at 
RT, followed by washing then incubation with biotinylated anti-mouse IgG, IgG1 and IgG2a 
antibodies (Abcam, Cambridge, MA, USA) mixed with HRP-conjugated Streptavidin (BD 
Biosciences, Franklin Lakes, NJ, USA) for 1 hour. Washed wells were then incubated with 
TMB substrate (KPL, Gaithersburg, MD, USA) for 10 min before the reaction was stopped 
with 1 M phosphoric acid and optical density measured at 450 nm (OD450 nm) using a 
VersaMax plate reader and analysed using SoftMax Pro software (Molecular Devices, 
Sunnyvale, CA, USA). Average OD450 nm values obtained from negative control wells were 
subtracted. 
 
2.10. Statistical and data analysis 
Statistical analysis was performed using GraphPad Prism 5.03 and CurveExpert Basic 1.4. 
Statistical analyses, including descriptive statistics, t-test and ANOVA with Bonferroni’s 
post-hoc test were used as appropriate, and p < 0.05 was considered significant. Image 
analysis was performed using ImageJ 1.46r (Wayne Rasband, National Institutes of Health). 
For the noninferiority analysis, we performed an independent t-test on the log transformed 
IgG data, and assessed whether the upper limit of the 95% confidence interval for the 
difference between treatments (low dose adjuvanted JJAV treatment minus standard high 
dose JJAV alone treatment) was below a predefined margin of non-inferiority of 0.5. 
 
2.11. Stability criteria 
Table I describes the acceptance criteria for the physicochemical and microbiological 















3.1  The effect of Advax on the allergenic potency of JJAV 
The allergenic potency of JJAV at baseline was not significantly affected by the presence of 
Advax in the formulation (p = 0.06‒0.99; Supplementary Table 1). The overall allergenic 
potency of JJAV with and without Advax was acceptable for at least 2 days when stored at 4 
and 25°C, with relative allergenic potencies between 102.4‒139.0% and 97.5‒144.9% for all 
stability samples stored at 4°C with and without Advax respectively, and between 100.2‒
134.3% and 94.3‒126.0% for all stability samples stored at 25°C with and without Advax 
respectively (Fig 1 and 2). A trend for a progressive increase in allergenic potency was 
observed in the 25 μg/mL JJAV stability samples, which continued to increase beyond the 
acceptable limits of 50‒150% after 14 days of storage at either 4 or 25°C, particularly for the 
stability samples with Advax (Fig 1). 
 
3.2 The effects of Advax on the stability of JJAV allergens 
Myr p 1 was the least stable of the 3 allergens that were quantified via UPLC-UV, and as 
such, stability was limited by the stability of Myr p 1 (Fig S1). Therefore, in the presence of 
Advax, the JJAV was stable for up to 7 and 3 days when stored at 4°C and 25°C, respectively 
(Fig 3). No significant differences were found between ‘with’ and ‘without’ Advax for either 
baseline samples (Supplementary Table 2) or for all but one of the stability pairs (Fig 3). 
SDS-PAGE results showed that a protein band at approximately 23 kDa disappeared slowly 
throughout the storage period and appeared to be replaced with new bands at approximately 
17, 19 and 21 kDa (Fig S2). The changes occurred regardless of sample treatments and were 
more obvious with prolonged storage. A similar pattern was also observed on the SDS-PAGE 
immunoblot results, whereby an IgE-binding band at 23 kDa slowly disappeared and was 
replaced with a new IgE-binding band at 19 kDa (Fig S3). The changes occurred regardless 
of Advax, and were most obvious in the stability samples stored at 25°C for 24 hours. 
 
3.3 The effects of Advax on JJAV diluent stability 
The addition of Advax did not cause a substantial change in the pH of JJAV diluent (Fig S4), 
and storage temperature had a minimal effect on the stability of benzyl alcohol for the period 














3.4 Size distribution of Advax microparticles formulated with JJA VIT 
Advax delta inulin microparticles had a mean hydrodynamic diameter of 1.6 μm at baseline 
(Fig 4A), and this did not change after storage at 4 and 25°C for up to 21 and 7 days 
respectively, but a two-fold increase in diameter was observed at the 28 day study endpoint at 
both 4 and 25°C. The polydispersity index (PdI) of Advax was approximately 0.6 at baseline 
and did not change substantially between day 1 and 21 of the study period, although there 
were noticeable fluctuations over time, particularly in the sample stored at 25°C, and the PdI 
increased to 1.0 at day 28 of study period at both 4 and 25°C (Fig 4B). 
 
3.5 Antimicrobial activity of JJA VIT formulated with Advax 
The batches of JJA VIT, JJAV diluents, and Advax were virtually free of endotoxins 
(Supplementary Table 3), and sterility testing of JJA VIT and JJAV diluents further 
supported the aseptic nature of the combined formulation (data not shown). All samples 
including JJAV diluent containing only JJAV and samples where Advax was added met the 
Pharmacopoeial requirements for antimicrobial activity at each sampling time point 
(Supplementary Table 4). 
 
3.6 Effect of Advax adjuvant on immunogenicity and tolerability of JJA VIT 
A murine immunogenicity model was used to test the hypothesis that Advax adjuvant could 
be used for JJAV dose sparing and to confirm that it had no negative effects on safety and 
tolerability. Female BALB/c mice, 6 to 8 week of age (n = 5/group), were immunized 4 times 
intramuscularly at 2-week intervals with JJAV 2 μg alone or combined with 1 mg Advax 
adjuvant versus JJAV 10 μg alone, with the aim to assess the non-inferiority of the JJAV 
specific IgG responses in the JJAV 2 μg + Advax low dose group when compared to the 
JJAV 10 μg high dose group. Blood samples were collected 2 weeks after the last 
immunization for measurement of JJAV-specific total IgG and IgG subtypes by ELISA. 
While only low or undetectable levels of JJAV-specific IgG were seen in animals immunised 
with 10 μg of JJAV alone, all animals in the low dose JJAV (2 μg) + Advax arm had 
detectable JJAV-specific IgG. A formal non-inferiority analysis performed using pre-
specified limits, confirmed the low dose JJAV + Advax arm was statistically non-inferior to 
the high dose JJAV alone group (p=0.976). A subsequent test of superiority confirmed that 
the JJAV-specific IgG responses in the low dose JJAV + Advax arm were superior (p=0.048) 
to those in the high dose alone arm (Fig. 5). Hence, Advax was confirmed to provide at least 













Advax adjuvant was predominantly through significant enhancement of specific IgG1 rather 
than IgG2a. No JJAV-specific IgE was detected in the sera of the immunized mice and no 
local (swelling, redness, hair loss) or systemic (weight loss, fever, inactivity, loss of 















Preclinical studies of novel adjuvanted allergen-specific immunotherapy (AIT) formulations 
are generally required by regulatory authorities prior to initiation of clinical trials. Such 
studies should demonstrate physicochemical and microbiological compatibility of the 
adjuvant with the antigenic components contained within the vaccines [21], together with 
immunogenicity data to justify the inclusion of the adjuvant in the vaccine. Although many 
human trials have been conducted on Advax adjuvant in combination with various infectious 
disease vaccines and one study of Advax with honeybee VIT [8, 13, 14], no information was 
previously available on the formulation, stability or immunogenicity of JJAV antigens in the 
presence of Advax. 
In the current study, we performed stability study of low-dose JJA VIT with and without 
Advax adjuvant, pre-packaged in plastic syringes thereby confirming that the JJA VIT and 
Advax components were compatible with each other, and minimal aggregation of delta inulin 
microparticles was observed in the period studied. Based on the data obtained, in particular 
the allergenic potency studies, low-dose JJA VIT formulated with Advax is both 
physicochemically and microbiologically stable for at least 2 days when stored at 4°C and 
25°C in plastic syringes. This will allow low-dose JJA VIT, formulated with or without 
Advax, to be prepared at a central pharmacy location in advance of clinical trial use and then 
transported to the site of patient administration, removing the need to prepare the vaccine at 
the patient’s bedside and may reduce the likelihood of errors in dosing occurring [22]. 
The JJAV stability results obtained in the current study are consistent with a previous report 
[17], although the conditions employed were somewhat different. In particular, the current 
study used U-100 plastic insulin syringes to store the samples and a lower concentration of 
JJAV was used than in the previous study. Measurement of total allergenic activity as 
determined by ELISA inhibition assay is required by regulatory bodies for the standardization 
and batch control of AIT products [23, 24]. The slight increase in JJAV allergenic activity 
with storage is entirely consistent with previous findings and this has been proposed to be due 
to conformational changes in the JJAV proteins in the presence of polysorbate 80 in the JJAV 
diluent [17]. Despite ELISA inhibition data indicating that the vast majority of allergenic 
activity was preserved, it does not exclude the possibility that one or more “minor” allergens 
might have degraded. This perhaps is better monitored using the immunoblot assay where we 
observed the shift down in the 22-23 kDa bands, recently found to be Phospholipase A2 













is consistent with prior findings and it was not affected by the inclusion of Advax in the 
formulation. Wanandy et al. recently reported the adsorption of Myr p 1 and Myr p 3 
allergens when JJAV API grade products were allowed to contact rubber stoppers for more 
than 24 hours [16]. Even though the low-dose JJAV in the current study was stored in plastic 
syringes with rubber plungers, negligible adsorption was identified. This difference might be 
due to the inclusion of polysorbate 80 as a surface active agent in the current samples, or 
different adsorption capacity and surface area of the rubbers. 
JJAV solutions above 25 μg/mL that are used for immunotherapy are intended for multi-dose 
use. The addition of benzyl alcohol as an antimicrobial preservative in the JJAV diluent is 
essential to reduce the risk of bacterial contamination [25, 26]. The insignificant change in 
the pH of the JJAV diluent in the presence of Advax was important as the solubility and 
optimal antimicrobial activity of benzyl alcohol is considerably reduced above pH 7 [17, 27]. 
When used as an antimicrobial preservative, benzyl alcohol is commonly added to parenteral 
preparations at a concentration between 0.75-5% [27, 28]. A 19% reduction of benzyl alcohol 
concentration in JJAV diluent due to dilutional effects from the addition of Advax reduced 
the concentration of benzyl alcohol to below this usual range and could therefore have 
affected its effectiveness as a preservative. However, the AET experiments confirmed that the 
antimicrobial efficacy of the combined formulation against challenged organisms was 
maintained throughout the study period. It is possible that this was due, at least in part, to the 
inherent antimicrobial activities of JJAV [29], which provided additive or synergistic effects 
to the preservative activity of benzyl alcohol. If this was the case, since low concentrations of 
venom proteins are used during the induction phase of a VIT, a greater reliance on the 
antimicrobial efficacy of benzyl alcohol is required during this phase. 
A PdI of <0.7 suggests a monodisperse preparation [18], and the results from these studies 
showed that Advax had a relatively monodisperse particle size distribution at the start of the 
study as indicated by the PdI of 0.6. The increase in average particle size and PdI observed at 
the end of study period may be caused by formation of delta inulin aggregates. However, the 
absence of multimodal peaks in all samples tested throughout the study period suggests that 
aggregation, if present, is limited under the study conditions employed and importantly the 
size of these particles was within the accepted range for stability (Table 1). Advax has been 
reported to have minimal protein adsorptive capacity [30], and similarly we found no 
evidence that Advax adsorbs JJAV allergens as there was minimal difference in the SDS-














Notably, the murine immunogenicity data supported the hypothesis that Advax adjuvant can 
provide significant antigen-sparing for JJA VIT, inducing significantly higher serum JJAV-
specific IgG levels in the mice that received the adjuvanted venom formulation than a five 
times higher dose of JJAV alone. Whilst there is currently no animal model of JJAV allergy, 
and hence the effects of Advax on inhibition of JJAV IgE during VIT or its ability to induce 
blocking IgG4 antibodies is unable to be assessed outside of human studies, the ability of 
Advax to enhance venom-specific IgG responses when compared to immunisation with 
venom alone has served as a useful predictive marker of favourable human responses in 
previous human studies of Advax-adjuvanted honeybee VIT, where inclusion of Advax led to 
an earlier and higher rise of venom-specific total IgG and IgG4 with potential blocking 
activity [13, 14]. Hence the current results support the rationale for a planned human trial of 
Advax combined with a reduced dose of JJAV (25 g in maintenance phase) as compared to 
the currently clinically proven 100 g maintenance JJAV dose. Notably, no safety or 
reactogenicity issues were identified with the Advax-adjuvanted low dose JJAV formulation 














5.  Conclusion  
Advax adjuvant provided at least 5-fold JJAV antigen sparing in murine immunogenicity 
studies, with no observed issues of reactogenicity or safety. No detrimental effects of Advax 
on JJAV stability were found, supporting use of this combined formulation as a JJAV-sparing 
strategy in planned human trials. Plans are in place to commence a human clinical trial to 
assess the ability of Advax to reduce the required maintenance dose of JJAV from 100 to 25 
g per dose, which if successful would result in a 4-fold higher number of subjects able to be 
treated with JJA VIT with current supplies, while also significantly reducing the potential 
cost of therapy, which largely reflects JJAV costs. 
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Table 1.   Acceptance criteria for physicochemical and microbiological stability of JJA VIT, 
JJAV diluent and Advax adjuvant 
 
Characteristic Assay Predetermined criteria  
JJAV allergens stability     
   Allergenic potency ELISA inhibition 50 - 150% relative to 
baseline 
   Individual allergen concentration UPLC-UV 75 - 150% relative to 
baseline 
   Protein profile SDS-PAGE Identical to baseline 
   Allergen profile SDS-PAGE immunoblot Identical to baseline 
 
JJAV diluent stability 
  
   Potential of hydrogen pH 5.9 - 6.3 
   Benzyl alcohol concentration UPLC-UV > 90% relative to baseline 
   
Advax adjuvant stability   




   Endotoxin content Limulus Amebocyte Lysate  
QCL-1000  
< 50 EU/ml 
   Preservative efficacy  Antimicrobial Efficacy 
Test 
 
1 x 105 - 1 x 106 
CFU/plate on baseline; ≥ 
1 log reduction relative to 
baseline on day 7;  ≥ 3 log 
reduction relative to 
baseline on day 14;                
no increase on day 28 
















Figure 1.   Effects of Advax (10 mg/mL) and storage temperature (4°C or 25°C) on the 
allergenic potency of JJAV (25 μg/mL) stored for up to 28 days. Analysis of allergenic 
potency was calculated as a percentage relative to baseline samples. Each sample was 
analysed in triplicate and presented as mean and SD. Asterisks designate significant 
differences (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
Figure 2.   Effects of Advax (5 mg/mL) and storage temperature (4°C or 25°C) on the 
allergenic potency of JJAV at (A) 0.1 μg/mL, (B) 1 μg/mL, and (C) 10 μg/mL stored for up 
to 2 days. Analysis was calculated as a percentage relative to baseline samples. Each sample 
was analysed in triplicate and presented as mean and SD. 
 
Figure 3.   Effects of Advax (10 mg/mL) and storage temperature (4°C or 25°C) on JJAV 
allergen peptides (A) Myr p 1, (B) Myr p 2, and (C) Myr p 3 in formulations of JJAV (25 
μg/mL) stored for up to 28 days. Analysis of remaining concentration of Myr p allergen 
peptides was calculated as a percentage relative to baseline samples. Each sample was 
analysed in triplicate and presented as mean and SD. Asterisks designate significant 
differences (*** p < 0.001). 
 
Figure 4.   Particle size distribution of Advax (10 mg/mL) as a function of (A) Z-average and 
(B) polydispersity index (PdI) when combined with JJAV (25 μg/mL) and stored for up to 28 
days at either 4°C or 25°C. Analysis was performed using diffraction light scattering 
technique. Each sample was analysed in triplicate and presented as mean and SD. 
 
Figure 5.   Antigen-sparing effect of Advax adjuvant on JJAV-specific IgG responses. 
Female BALB/c mice, 6 to 8 week old (n=5/group) were immunized 4 times i.m. at 2-week 
intervals with JJAV 2 μg alone or with Advax 1 mg compared to a 5-fold higher dose of 
JJAV 10 μg alone, all in 50 μL total volume. Blood samples were collected 2 weeks after the 
last immunization and JJAV-specific IgG, IgG1 and IgG2a measured by ELISA (* p < 0.05, 
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